ArticleBritish journal of cancer2008
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.Future oncology (London, England) · 2014Pooled it
- Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach.Pharmacoepidemiology and drug safety · 2025Article
- The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer - Trial protocol of a phase II study.Contemporary clinical trials communications · 2021Article
- Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.Acta oncologica (Stockholm, Sweden) · 2018Article
- Breast cancer recurrence after reoperation for surgical bleeding.The British journal of surgery · 2017Article
- Breast cancer recurrence in relation to antidepressant use.Cancer causes & control : CCC · 2016Article
- Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.British journal of clinical pharmacology · 2014Article
- CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application.Metabolic brain disease · 2012Article
- Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Expert review of clinical pharmacology · 2011Review
- CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Journal of the National Cancer Institute · 2011Article
- Existing data sources for clinical epidemiology: Aarhus University Prescription Database.Clinical epidemiology · 2010Article
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.Acta oncologica (Stockholm, Sweden) · 2010Article
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.BMJ (Clinical research ed.) · 2010Article
- No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Article
- CYP2D6 and tamoxifen: DNA matters in breast cancer.Nature reviews. Cancer · 2009Review
- Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.Breast cancer research : BCR · 2008Article
- Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours. Cytochrome P-450 2D6 metabolizes tamoxifen to metabolites that more readily bind the oestrogen receptor. This enzyme also metabolizes selective serotonin reuptake inhibitors (SSRI), so these widely used drugs - when taken concurrently - may reduce tamoxifen's prevention of breast cancer recurrence. We studied citalopram use in 184 cases of breast cancer recurrence and 184 matched controls without recurrence after equivalent follow-up. Cases and controls were nested in a population of female residents of Northern Denmark with stages I-III oestrogen-receptor-positive breast cancer 1985-2001 and who took tamoxifen for 1, 2, or most often for 5 years. We ascertained prescription histories by linking participants' central personal registry numbers to prescription databases from the National Health Service. Seventeen cases (9%) and 21 controls (11%) received at least one prescription for the SSRI citalopram while taking tamoxifen (adjusted conditional odds ratio=0.85, 95% confidence interval=0.42, 1.7). We also observed no reduction of tamoxifen effectiveness among regular citalopram users (>or=30% overlap with tamoxifen use). These results suggest that concurrent use of citalopram does not reduce tamoxifen's prevention of breast cancer recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.